Key Market Players Paving the Way for Advancements in Exosome-Based Diagnostics and Therapeutics
Exosome Research Market
Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.The global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period.
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities. The kits & reagents segment is expected to grow at the highest CAGR during the study period.As academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and analysis.The standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and monitoring.With the growing interest in exosome-based diagnostics - especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer's and Parkinson's - laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted therapies.North America is expected to grow at the highest CAGR in the global exosome research market from 2025 to 2030.North America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple University.Their investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays.
Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America's status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research sector.The report provides insights on the following pointers:
Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading).
Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market.
Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market.
Key Attributes:
Report Attribute
Details
No. of Pages
325
Forecast Period
2025 - 2030
Estimated Market Value (USD) in 2025
$214.4 Million
Forecasted Market Value (USD) by 2030
$480.6 Million
Compound Annual Growth Rate
17.5%
Regions Covered
Global
Companies Featured
Thermo Fisher Scientific Inc.
Qiagen
Lonza
Danaher
Bio-Techne
System Biosciences, LLC
Amsbio
Roosterbio, Inc.
Miltenyi Biotec
Norgen Biotek Corp.
Aethlon Medical, Inc.
Creative Medical Technologies Holdings, Inc.
Spectris
Nanofcm, Inc.
Izon Science Limited
Capricor Therapeutics, Inc.
Anjarium Biosciences AG
Ciloa
Innovaprep
Ilias Biologics Inc.
Unchained Labs
Rion Inc.
Cell Guidance System LLC
Inoviq
Nx Pharmagen
Exopharm
Everzom
Nanosomix
Creative Biolabs
For more information about this report visit https://www.researchandmarkets.com/r/e5q5hd
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Exosome Research Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Here's Why 3M Shares Slumped Today (and Why It Could Be a Good Buying Opportunity)
Key Points 3M raised its margin, earnings, and implied cash flow guidance, but lowered its full-year revenue growth expectations. Management is making excellent progress on improving the business operationally. 10 stocks we like better than 3M › 3M (NYSE: MMM) stock declined by 5.2% as of 2 p.m. ET today following the company's second-quarter earnings report. Despite the disappointing share price reaction, the results were solid, and there was plenty in the results to make investors feel that management is taking the company in the right direction. The bad and good news for 3M Starting with the bad news: 3M's end markets aren't improving as much as management had hoped at the start of the year. After nudging investors toward the low end of its initial full-year organic growth range of 2%-3% in April, CEO Bill Brown lowered it to 2%. That's probably the reason for the decline, compounded by management citing softness in key end markets for 3M, like consumer electronics, a challenged auto aftermarket, and a barely improving auto original equipment market. That said, there's little management can do about its end markets, but it can improve its operational performance. And the good news is, it's doing it very well. Some highlights from the report: New product introductions of 126 put it well on track to exceed its target of 215 in 2025. On-time-in-full (OTIF) deliveries at the highest level in nearly six years -- a key measure management is targeting. "Better asset utilization enabling the sunset of old equipment" Management raised full-year operating profit expansion guidance to 150 basis points to 200 basis points, from its original guidance of 130 basis points to 190 basis points. Full-year earnings per share guidance has been increased to $7.75-$8.00 from $7.60-$7.90 previously. In short, the company's self-help initiatives are effective, but the stock is being penalized due to end-market challenges. As such, the dip presents a buying opportunity, provided there's some stabilization in the consumer electronics and auto sectors, but that might require lower interest rates first. Do the experts think 3M is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did 3M make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,069% vs. just 180% for the S&P — that is beating the market by 888.61%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 3M. The Motley Fool has a disclosure policy. Here's Why 3M Shares Slumped Today (and Why It Could Be a Good Buying Opportunity) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Opendoor stock on track for 170% weekly gain as retail frenzy cements meme status
After a trading day that has already seen Opendoor Technologies' (OPEN) stock price rocket upward another 20%, the iBuyer penny stock looks on track to deliver a 170% gain on the week. Following a bull thesis for an Opendoor turnaround posted to X on July 14 by EMJ Capital principal and Carvana (CVNA) spotter Eric Jackson, the stock has firmly entered retail meme stock status. Retail trading activity in Opendoor stock has increased 140% over the past 10 days compared to the preceding month, according to retail investor data provider VandaTrack. After reaching a high of $39.24 in February 2021, shares of Opendoor have fallen to under $1 each. The latest retail rally, fueled by Jackson's thesis and speculative posts on the meme-stock Reddit forum r/WallStreetBets, has begun to push the company toward the $5 line that would lift it out of penny stock status. The question for Opendoor leadership will be what it can do to maintain the momentum and potentially reach Jackson's price target of $82 per share. Opendoor uses iBuyer real estate technology to buy homes from owners for cash, make light repairs, then flip them back onto the open market to hopefully resell at a profit. Jackson told Yahoo Finance that while he isn't currently making an overt activist play on the company, he has heard several ideas that, "if you waved a magic wand and suddenly [the ideas] were announced this afternoon, [I] think would cause an eruption upwards in the shares." Read more about Opendoor's stock moves and today's market action. Several factors contributed to Opendoor's stock price falling below a dollar. The combination of a declining housing market and rising interest rates put pressure on the company's bottom line at the macro level, and its heavy use of borrowing to acquire and quickly flip homes has saddled the company with debt. As Jackson noted in his X thread, Opendoor has never notched a quarter of positive EBITDA. After spending more than 30 days trading below $1, Opendoor disclosed to investors in May that it had received warning of a possible delisting from the Nasdaq. And in June, the company agreed to pay $39 million to settle a class-action lawsuit brought in 2022 by investors who claimed the company failed to disclose that its pricing algorithms are not equipped to adapt to shifting conditions in the housing market. But investors see a tailwind. Jackson noted in his X thread that he expects Opendoor to report its first quarter of positive EBITDA in August and complimented the company's new experimentation with partnering with real estate brokers instead of constantly competing with them. With housing market giants Zillow (Z) and Redfin having exited the iBuyer game as of 2021 and 2022, respectively, the company faces little competition. For now, retail investors are piling into a bet that Opendoor could be the next Carvana. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
23 minutes ago
- Yahoo
The List of Gold IRA Companies for 2025 Released by Affiliate Credo
Disclosure: The owners of this website may be compensated for referrals or recommendations made in this content. The opinions expressed may not be neutral or independent. NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Affiliate Credo, a financial content publisher based in New York, has released its annual research summary analyzing key developments in the U.S. Gold IRA industry for 2025. This report offers insights into notable players in the physical asset retirement market and highlights general market characteristics observed in the self-directed retirement industry. The 2025 research emphasizes transparency, educational support, and service accessibility as primary factors influencing consumer engagement with Gold IRA companies. Key Highlights from the 2025 Research Report Each company mentioned below offers its own free Gold IRA Kit with educational materials. You can request it directly on their website to learn more about their services. A trusted company focused on customer education and long-term support offers a highly structured onboarding process for retirement-focused individuals. One of the leading firms in rollover services helps customers streamline their IRA and 401(k) transitions with efficient and responsive support. A company that actively appeals to first-time customers offers transparent account minimums and easy onboarding options to start your precious metals journey. A provider offering gold, silver, platinum, and palladium stands out for its informative materials and direct communication approach. One digital-forward platform integrates live pricing tools and online dashboards to help manage physical asset portfolios more clearly and efficiently. This research aims to provide consumers with an overview of popular companies currently active in the Gold IRA space and to support broader financial literacy in retirement planning. About Affiliate CredoAffiliate Credo is a New York–based financial content publisher specializing in retirement research, educational materials, and comparative analysis across investment-related products. The platform is committed to improving access to clear and unbiased information that helps Americans make well-informed financial decisions. Media Contact:Affiliate CredoNew York, USAEmail: A photo accompanying this announcement is available at
